US Stock Market Move | Treatment of genetic bone diseases in the research drug clinical trial failed, Ultragenyx Pharmaceutical (RARE.US) plunges over 42% in pre-market trading.
As of the filing, the stock is down over 42%, trading at $19.69.
Before Monday's US stock market opening, Ultragenyx Pharmaceutical (RARE.US) stock price plummeted. As of press time, the stock has fallen more than 42% to $19.69. On the news front, the company announced that its investigational drug for treating a specific genetic bone disease did not meet the primary efficacy endpoint in late-stage clinical trials.
Related Articles
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
